The demand for minimal residual disease testing is increasing mainly due to the higher prevalence of solid tumors and blood cancers like leukemia, multiple myeloma, and lymphoma. Continuous advances in molecular diagnostics have greatly improved MRD detection accuracy, and active product development and launches by leading companies are further boosting the market's momentum.
LAS VEGAS, Aug. 20, 2025 /PRNewswire/ -- DelveInsight's Minimal Residual Disease Testing Market Insights report provides the current and forecast market analysis, individual leading minimal residual disease testing companies' market shares, challenges, minimal residual disease testing market drivers, barriers, trends, and key market minimal residual disease testing companies in the market.
Key Takeaways from the Minimal Residual Disease Testing Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global minimal residual disease testing market during the forecast period.
- In the test type segment of the minimal residual disease testing market, the polymerase chain reaction category accounted for the largest market share in 2024.
- Notable minimal residual disease testing companies such as F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Personalis, Inc., Guardant Health, NeoGenomics Laboratories, Exact Sciences, Foundation Medicine, QIAGEN, Adaptive Biotechnologies, Foresight Diagnostics, ICON plc, Integrated DNA Technologies, Inc., 3B BlacBio Biotech India, Bioartis, EntroGen, Natera, Inc., Labcorp, Bio-Rad Laboratories, Inc., Sysmex Corporation, Veracyte, Inc., Cognixion, Inc., and several others, are currently operating in the minimal residual disease testing market.
- In June 2025, QIAGEN expanded its minimal residual disease (MRD) testing portfolio through new strategic partnerships with Tracer Biotechnologies and Foresight Diagnostics. These collaborations aim to strengthen QIAGEN's presence in MRD testing for both solid tumors and blood cancers.
- In April 2025, Labcorp announced the expansion of its precision oncology portfolio with two key solutions. The first, Labcorp Plasma Detect, is designed to help assess the risk of disease recurrence in patients with stage III colon cancer. The second, PGDx elio plasma focus Dx, is the first and only FDA-authorized kitted liquid biopsy test for pan-solid tumors, aimed at identifying patients who may benefit from targeted therapies.
- In January 2025, Adaptive Biotechnologies Corporation announced a multi-year exclusive strategic commercial collaboration aimed at advancing MRD monitoring for patients with select blood cancers. The partnership combines Adaptive's clonoSEQ® MRD test with NeoGenomics' COMPASS and CHART assessment services, providing clinicians and patients with deeper insights throughout the treatment journey.
To read more about the latest highlights related to the minimal residual disease testing market, get a snapshot of the key highlights entailed in the Global Minimal Residual Disease Testing Market Report
Minimal Residual Disease Testing Overview
Minimal residual disease testing refers to the detection of small numbers of cancer cells that may remain in a patient's body after treatment and are undetectable through standard diagnostic methods. These residual cells can eventually lead to relapse, so identifying them early is critical for managing and monitoring the disease. MRD testing uses highly sensitive techniques such as PCR, next-generation sequencing (NGS), or flow cytometry to quantify these remaining cancer cells at very low levels. It has become particularly important in hematologic malignancies like leukemia and multiple myeloma, where MRD status is an increasingly important prognostic indicator.
Clinicians use MRD results to help assess treatment efficacy and to make decisions about therapy intensification or discontinuation. A negative MRD result often indicates a deeper and more durable response to treatment and is associated with improved survival outcomes. Conversely, the presence of MRD can prompt early therapeutic interventions to prevent full relapse. As diagnostic technology advances, MRD testing is being incorporated into clinical guidelines and drug development as a surrogate endpoint, making it a powerful tool for personalized treatment strategies in oncology.
Minimal Residual Disease Testing Market Insights
North America is expected to account for the largest share of the minimal residual disease testing market, driven by multiple key factors. The region's leadership stems largely from the increasing incidence of blood cancers and solid tumors, which is boosting the need for sophisticated diagnostic tools. Furthermore, rapid progress in molecular diagnostic technologies, along with consistent product launches and regulatory approvals by major companies, continues to accelerate market expansion.
In the U.S., the market is further buoyed by ongoing innovation and strategic initiatives from leading industry players. For example, in February 2025, Myriad Genetics received a foundational patent from the U.S. Patent and Trademark Office for its tumor-informed, high-definition MRD assay, which enhances ctDNA detection using advanced sequencing technologies to achieve highly accurate MRD measurement. Likewise, in May 2025, Exact Sciences Corp. released clinical validation data from its Beta-CORRECT study under the GALAXY cohort, confirming that its Oncodetect MRD test effectively predicts recurrence in stage II-IV colorectal cancer patients, supporting its use in post-treatment monitoring and therapeutic decision-making.
As a result, the combination of growing cancer incidence, advancements in molecular diagnostics, and continuous technological progress with new MRD testing products is projected to substantially drive the growth of the MRD testing market in North America from 2025 to 2032.
To know more about why North America is leading the market growth in the minimal residual disease testing market, get a snapshot of the Minimal Residual Disease Testing Market Outlook
Minimal Residual Disease Testing Market Dynamics
The minimal residual disease testing market is experiencing strong growth, driven largely by the increasing prevalence of hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. As cancer treatment becomes more personalized, oncologists are relying heavily on MRD testing to detect trace levels of cancer cells that remain after treatment. This enables earlier intervention and more tailored therapy decisions, which is pushing hospitals and cancer research centers to adopt advanced MRD technologies.
Technological advancements are a major catalyst in shaping market dynamics. Highly sensitive next-generation sequencing (NGS), digital PCR, and flow cytometry platforms are enabling clinicians to monitor disease burden with far greater precision than ever before. As these tests prove their clinical value in improving patient outcomes, major diagnostic companies are investing heavily in R&D and launching new MRD assays. Moreover, regulatory agencies like the FDA are granting clearances and approvals for new MRD tests, building confidence among healthcare providers and accelerating market adoption.
Strategic collaborations between diagnostic companies and pharmaceutical firms are also contributing to growth. Pharma companies increasingly incorporate MRD status as a key endpoint in clinical trials for novel oncology drugs. This is boosting the demand for companion diagnostics and driving partnerships across the value chain. Venture capital investment in MRD testing startups is also rising, which adds to innovation and competition in the market.
However, market expansion still faces challenges. Despite significant progress, the high cost of advanced MRD testing technologies and limited reimbursement in some regions can hinder widespread adoption. Healthcare systems in emerging markets may lack access to sophisticated lab infrastructure needed for these tests. In addition, there is still variability in standardization across different MRD techniques, making it difficult to compare results across platforms and institutions.
Get a sneak peek at the minimal residual disease testing market dynamics @ Minimal Residual Disease Testing Market Dynamics Analysis
Report Metrics | Details |
Coverage | Global |
Study Period | 2022-2032 |
Minimal Residual Disease Testing Market CAGR | ~11% |
Minimal Residual Disease Testing Market Size by 2032 | USD 4.5 Billion |
Key Minimal Residual Disease Testing Companies | F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Personalis, Inc., Guardant Health, NeoGenomics Laboratories, Exact Sciences, Foundation Medicine, QIAGEN, Adaptive Biotechnologies, Foresight Diagnostics, ICON plc, Integrated DNA Technologies, Inc., 3B BlacBio Biotech India, Bioartis, EntroGen, Natera, Inc., Labcorp, Bio-Rad Laboratories, Inc., Sysmex Corporation, Veracyte, Inc., Cognixion, Inc., and others |
Minimal Residual Disease Testing Market Assessment
- Minimal Residual Disease Testing Market Segmentation
- Minimal Residual Disease Testing Market Segmentation By Test Type: Polymerase Chain Reaction, Flow Cytometry, Next Generation Sequencing, and Others
- Minimal Residual Disease Testing Market Segmentation By Application: Leukemia, Lymphoma, Solid Tumors, and Others
- Minimal Residual Disease Testing Market Segmentation By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, and Research Centers
- Minimal Residual Disease Testing Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
Which MedTech key players in the minimal residual disease testing market are set to emerge as the trendsetter explore @ Minimal Residual Disease Testing Companies
Table of Contents
1 | Minimal Residual Disease Testing Market Report Introduction |
2 | Minimal Residual Disease Testing Market Executive Summary |
3 | Competitive Landscape |
4 | Regulatory Analysis |
5 | Minimal Residual Disease Testing Market Key Factors Analysis |
6 | Minimal Residual Disease Testing Market Porter's Five Forces Analysis |
7 | Minimal Residual Disease Testing Market Layout |
8 | Minimal Residual Disease Testing Market Company and Product Profiles |
9 | KOL Views |
10 | Project Approach |
11 | About DelveInsight |
12 | Disclaimer & Contact Us |
Interested in knowing the minimal residual disease testing market by 2032? Click to get a snapshot of the Minimal Residual Disease Testing Market Trends
Related Reports
Minimal Residual Disease Market
Minimal Residual Disease Market Insight, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key MRD companies, including Adaptive Biotechnologies, Bristol-Myers Squibb Company, Natera, Kite Pharma, Amgen Inc., among others.
Polymerase Chain Reaction Market
Polymerase Chain Reaction Market Insights, Competitive Landscape, and Market Forecast - 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key PCR companies, including Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Qiagen, Agilent Technologies Inc., Standard Biotools, F. Hoffmann-La Roche Ltd., Eppendorf, Avance Biosciences Inc., Merck & Co. Inc., Abbott, Promega Corporation, Takara Bio Inc., Endress+Hauser Group Services AG, BioMérieux, GenMark Diagnostics Inc., Grifols SA, Hologic Inc., BD, Sysmex Corporation, Stilla, among others.
Next Generation Sequencing Market
Next Generation Sequencing Market Insights, Competitive Landscape, and Market Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key next generation sequencing companies, including Agilent Technologies, Inc., Illumina Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, QIAGEN, Thermo Fisher Scientific, PerkinElmer Inc., MedGenome, BGI, Pacific Biosciences, GENEWIZ, Oxford Nanopore Technologies plc., Psomagen, Inc., 10x Genomics, Takara Bio Inc., Zymo Research Corporation., NuGEN Technologies, Inc. (Tecan Trading AG), Vela Diagnostics, CD Genomics., HTG Molecular Diagnostics, Inc., among others.
Flow Cytometry Market
Flow Cytometry Market Insight, Competitive Landscape, and Market Forecast - 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key flow cytometry companies, including Thermo Fisher Scientific Inc., BD, Stratedigm, Inc, Bio-Rad Laboratories, Inc., Luminex Corporation., Miltenyi Biotec, Sysmex Corporation, Agilent Technologies, Inc., Sony Biotechnology Inc., bioMérieux SA, Enzo Life Sciences, Inc., Union Biometrica, Inc., Cytek Biosciences, Sartorius AG, Beckman Coulter, Inc., Apogee Flow Systems Ltd., Molecular Instruments, Inc., Integrated DNA Technologies, Inc., New England Biolabs (NEB), ACROBiosystems, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
https://www.delveinsight.com/medical-devices
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/global-minimal-residual-disease-testing-market-gearing-up-for-outstanding-expansion-at-a-cagr-of-11-by-2032--delveinsight-302534343.html
